(Q26774223)

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

ChEBI release 2020-05-28

1 reference

Adrian S Ray

1

0 references

author name string

Marshall W Fordyce

series ordinal

2

0 references

Michael J M Hitchcock

series ordinal

3

0 references

language of work or name

English

0 references

publication date

January 2016

0 references

published in

Antiviral Research

0 references

volume

125

0 references

page(s)

63-70

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Distribution of lysosomal protective protein in human tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Osteoporosis and bone health in HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Perspectives on the development of acyclic nucleotide analogs as antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

CD4+ count-guided interruption of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Effect of early versus deferred antiretroviral therapy for HIV on survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Continuous antiretroviral therapy decreases bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Renal function with use of a tenofovir-containing initial antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Projected life expectancy of people with HIV according to timing of diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Association of tenofovir exposure with kidney disease risk in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Markers of renal disease and function are associated with systemic inflammation in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Mechanism of active renal tubular efflux of tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANTIVIRAL.2015.11.009

7 January 2021